Tomoharu Shimizu

Tomoharu Shimizu


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2007 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YKYoshimasa Kurumi
Yoshimasa Kurumi
TTTohru Tani
Tohru Tani
SNShigeyuki Naka
Shigeyuki Naka
HSHisanori Shiomi
Hisanori Shiomi
TSTomoharu Shimizu
Tomoharu Shimizu
SMShigehiro Morikawa
Shigehiro Morikawa

1 January 2014 in International Surgery
Verified
Journal Article
Closed access
YNYoshinobu Nagasawa
Yoshinobu Nagasawa
TSTomoharu Shimizu
Tomoharu Shimizu
HSHiromichi Sonoda
Hiromichi Sonoda
EMEiji Mekata
Eiji Mekata
MWMasato Wakabayashi
Masato Wakabayashi
TTTohru Tani
Tohru Tani
Totally implantable access ports (TIAPs) are generally used in oncology. Few studies have addressed complications associated with the insertion site. A total of 233 consecutive oncology patients were enrolled to receive TIAP inserts via internal jugular vein (IJV) or subclavian vein (SV). Data on clinicopathologic parameters and early/late complications were retrospectively collected. No differences were found early and late complication rates. Catheter injury was observed more frequently in the IJV group (2.9%) than in the SV group (1.0%) without statistical significance. Multivariate logistic regression analysis showed that age, switch to palliative use of TIAP, and the distribution of diseases (low risk in patients with colorectal cancer) were independent risk factors for determining complications. In conclusion, TIAP insertion site showed no impact on the early and late complication rates. Catheter injury appears to occur at the same frequency with both approaches. Therefore, medical doctors may choose their preferred puncture site when performing TIAP insertion.

1 June 2017 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
TSTomoharu Shimizu
Tomoharu Shimizu
TMToru Miyake
Toru Miyake
MTMasaji Tani
Masaji Tani
Toraymyxin® (Toray Medical Co., Ltd, Tokyo, Japan) has been developed as a direct hemoperfusion column that contains polymyxin B‐immobilized fiber to bind endotoxins in patients’ blood. Toraymyxin was approved by the Japanese National Health Insurance system for the treatment of endotoxemia and septic shock in 1994. Since then, PMX (defined as direct hemoperfusion with Toraymyxin) has been safely used in more than 100 000 cases in emergency and intensive care units in Japan. Toraymyxin is currently available for use in clinical settings in 12 countries outside of Japan. We reviewed and analyzed the development, clinical use, and efficacy of Toraymyxin, and assessed the current status of Toraymyxin use for the treatment of severe sepsis and septic shock. Our review shows that PMX appeared to be effective in improving hemodynamics and respiratory function in septic shock requiring emergency abdominal surgery. Recent large‐scale ranomized controlled trialscould not demonstrate whether prognosis is improved by PMX. However, the latest meta‐analysis revealed that PMX significantly decreased mortality in patients with severe sepsis and septic shock. Combination of PMX with continuous hemodiafiltration and longer duration of PMX might be an effective strategy to improve survival in such patients.

15 November 2013 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
YKYu Kobayashi
Yu Kobayashi
ATAtsushi Takano
Atsushi Takano
YMyohei miyagi
yohei miyagi
ETEiju Tsuchiya
Eiju Tsuchiya
HSHiromichi Sonoda
Hiromichi Sonoda
YDYataro Daigo
Yataro Daigo
To identify new cancer biomarkers and therapeutic targets for colorectal cancers (CRCs), we performed immunohistochemical analysis using tissue microarrays covering archival tumor tissue samples from 434 CRC patients and antibodies to cell division cycle-associated protein 1 (CDCA1) that was originally identified as an oncoantigen by our gene expression profile database, and compared its expression with several clinicopathological factors. Strong CDCA1 positivity was associated with poorer prognosis for patients with CRC (P=0.019) and multivariate analysis confirmed its independent prognostic value. In addition, transfection of siRNAs against CDCA1 suppressed its expression and induced apoptosis of CRC cells. These results suggest that CDCA1 could be a prognostic biomarker and a potential therapeutic target for CRCs.

1 July 2021 in European Surgical Research
Verified
Journal Article
Open access
PDF file
TMToru Miyake
Toru Miyake
HMHaruki Mori
Haruki Mori
DYDaiki Yasukawa
Daiki Yasukawa
ZHZhang Hexun
Zhang Hexun
HMHiromitsu Maehira
Hiromitsu Maehira
MTMasaji Tani
Masaji Tani
Introduction: Microbiomes play a vital role in the development and progression of cancer. The clinical status, including prognosis, genetic mutations, and sensitivity to chemotherapy, differs depending on the location of colorectal cancer (CRC); however, the association between gut microbiota and the location of CRC is not entirely understood. This study was conducted to evaluate the differences in the gut microbiota in patients with CRC according to the location of the tumor. Methods: Fifty-six patients who underwent surgery for CRC between August 2018 and November 2019 were included in the study. Three patients who had received neoadjuvant therapy or antibiotic treatment within 1 month before surgery were excluded. The metagenomes of microbiota in preoperative feces were assessed using the V3–V4 region of 16s rRNA amplicon sequences. Results: The beta diversity of the Bray-Curtis distance was significantly higher in left-sided than in right-sided CRC. Fusobacterium predominated in left-sided CRC according to the linear discriminant analysis effect size method. Blautia, Eryspelotrichales, Holdemanella, Faecalibacterium, Subdoligranulum, and Dorea constituted the dominant intestinal flora in right-sided CRC. Pathway analysis revealed that L-lysine fermentation and cob(II)yrinate a,c-diamide biosynthesis I were predominant in left-sided CRC. Discussion: This study demonstrated that fecal microbiota in left-sided CRC constitutionally and functionally differ from those in right-side CRC. These results will help to elucidate the biological differences according to tumor location and develop treatments for human CRC.

29 August 2017 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
PDF file
TSTomoharu Shimizu
Tomoharu Shimizu
TMToru Miyake
Toru Miyake
NKNaomi Kitamura
Naomi Kitamura
MTMasaji Tani
Masaji Tani
YEYoshihiro Endo
Yoshihiro Endo